NDT Advance Access published online on July 25, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn401
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Severe everolimus-associated pneumonitis in a renal transplant recipient
1 Nephrology Unit 2 Intensive Care Unit, Fundación Jiménez Díaz-Capio, Universidad Autónoma, Madrid, Spain
Correspondence and offprint requests to: Simona Alexandru, Nephrology Unit, Fundación Jiménez Díaz-Capio, Av Reyes Catolicos 2, 28040 Madrid, Spain. Tel: +34-9155-04940; Fax: +34-9155-42636; E-mail: salexandru{at}fjd.es, simona_amely{at}yahoo.com
| Abstract |
|---|
Inhibitors of mTOR (mammalian target of rapamycin) are immunosuppressants with less nephrotoxic potential than calcineurin inhibitors and antiproliferative effects, which are advantageous in the case of malignancy. However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis. To our knowledge, only one case of a pneumonitis associated with everolimus in a heart transplant patient has been reported, and it was related to elevated trough blood levels. We report herein the first case of a kidney graft recipient who developed everolimus-associated pneumonitis with normal trough blood levels that was completely reversed after drug withdrawal.
Keywords: everolimus; pneumonitis; sirolimus; transplantation
Received for publication: 17. 3.08
Accepted in revised form: 24. 6.08